B. Riley analyst Kyle Bauser raised the firm’s price target on LifeMD (LFMD) to $12 from $11 and keeps a Buy rating on the shares following the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD sees Q4 revenue $57M-$58M, consensus $57.34M
- LifeMD backs FY24 revenue view at least $205M, consensus $206M
- LifeMD reports Q3 EPS (14c), consensus (12c)
- LifeMD launches affiliated pharmacy to drive end-to-end patient care
- LifeMD launches TestoRx, direct to consumer testosterone replacement therapy